Sikander Ailawadhi, MD, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia.
Sikander Ailawadhi, MD, consultant, Division of Hematology/Oncology, Department of Internal Medicine, professor of medicine, Division of Hematology/Oncology, Departments of Medicine and Cancer Biology, Mayo Clinic, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia (CLL).
During the 2021 ASCO Annual Meeting, findings from a phase 1 study demonstrated encouraging activity with the novel BCL-2 inhibitor lisaftoclax in patients with relapsed/refractory CLL and small lymphocytic lymphoma.
The study is ongoing, says Ailawadhi. The recommended phase 2 dose of 600 mg of lisaftoclax is being evaluated in patients with a high risk of developing tumor lysis syndrome (TLS), Ailawadhi says. Additionally, the final patient with a low risk of developing TLS has consented to treatment with lisaftoclax, so if the safety data prove favorable, the phase 2 expansion study will likely commence in that patient cohort, Ailawadhi explains.
Notably, 3 ongoing studies evaluating lisaftoclax are ongoing in CLL, multiple myeloma, and Waldenström macroglobulinemia, concludes Ailawadhi.